Composition for relieving hangovers and improving liver function containing powdered raw materials, and method for producing the same

Abstract

The present invention relates to a composition containing L-ornithine for relieving hangovers and improving liver function, and a method for producing the same. The present invention has the advantage of exerting a sufficient hangover relief effect while minimizing the burden on the human body. Therefore, the examples of the present invention provide hangover relief and liver function improvement effects.

Description

[Technical Field]

[0001] The following examples relate to compositions containing powdered raw materials for relieving hangovers and improving liver function, and methods for producing the same. [Background technology]

[0002] Approximately 10% of the ethanol absorbed through drinking is excreted from the body through breathing and urination, while the remaining 90% is metabolized in the digestive system and liver. Alcohol is metabolized in the liver, where it is oxidized to acetaldehyde by alcohol dehydrogenase (ADH), and this acetaldehyde is then oxidized to acetic acid by acetaldehyde dehydrogenase (ALDH). Both of these oxidation processes require NAD (nicotinamide adenine dinucleotide). The resulting acetic acid is converted to carbon dioxide and water by acetyl coenzyme A, with the carbon dioxide being excreted through the lungs and the water being excreted through urination. Excessive alcohol intake induces hangovers, which cause alcohol and acetaldehyde to accumulate in the body, acting as major toxic substances in various organs and causing negative effects on the body such as headaches, fatigue, sensitivity to light and sound, muscle pain, bloodshot eyes, thirst, nausea, vomiting, and stomach pain.

[0003] To alleviate hangovers, Korean Patent Publication No. 10-0853078 discloses the development of a wide variety of functional beverages or compositions, particularly those containing ingredients extracted from natural materials. These functional beverages are consumed alone after drinking or added to high-alcohol beverages before drinking. However, the reality is that these beverages are not very effective in relieving hangovers. Furthermore, some herbal energy drinks may cause abdominal distension and pain, raising concerns about their harmful effects on the human body. Therefore, there is a need to develop a composition that provides sufficient hangover relief while minimizing the burden on the human body. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Republic of Korea Patent No. 10-0853078 Summary of the Invention [Problem to be solved by the invention]

[0005] The following examples have been devised to solve the above-mentioned problems, and the object of the present invention is to provide a composition that exerts a sufficient hangover relief effect while placing little strain on the human body, and a method for producing the same. [Means for solving the problem]

[0006] To achieve the above-mentioned object of the present invention, one embodiment of the present invention provides a food composition for relieving hangovers and improving liver function, comprising L-ornithine, potassium citrate, cabbage powder, and one or more lactic acid bacteria selected from the group consisting of bifidobacteria and lactobacillus, and a method for producing the same.

[0007] One embodiment of the present invention provides a method for preparing a food composition for relieving hangovers and improving liver function, comprising the steps of extracting and drying cabbage to prepare cabbage powder; and mixing the cabbage powder with L-ornithine, potassium citrate, and one or more lactic acid bacteria selected from the group consisting of bifidobacteria and lactobacillus. [Effects of the Invention]

[0008] The present invention has the advantage of exerting a sufficient hangover relief effect while placing little strain on the human body. Therefore, the embodiments of the present invention provide hangover relief and liver function improvement effects. DETAILED DESCRIPTION OF THE INVENTION

[0009] Hereinafter, the embodiments will be described in detail with reference to the accompanying drawings. However, various modifications may be made to the embodiments, and the scope of the patent application is not limited to or restricted by such embodiments. It should be understood that all modifications, equivalents, or alternatives to the embodiments are included in the scope of the patent.

[0010] Specific structural or functional descriptions of the embodiments are disclosed for illustrative purposes only and may be modified and implemented in various forms. Therefore, the embodiments are not limited to the specific disclosed forms, and the scope of this specification includes modifications, equivalents, or alternatives that fall within the technical spirit.

[0011] Although terms such as "first" or "second" may be used to describe various components, such terms should be construed only to distinguish one component from another. For example, a first component may be named a second component, and similarly, a second component may be named a first component.

[0012] When a component is referred to as being "coupled" to another component, it may be directly coupled or connected to the other component, but it should be understood that there may be other components in between.

[0013] The terms used in the examples are for explanatory purposes only and should not be construed as limiting. A singular expression includes a plural expression unless the context clearly dictates otherwise. In this specification, the terms "comprise" or "have" are intended to specify the presence of features, numbers, steps, operations, components, parts, or combinations thereof described in the specification, and should be understood not to preclude the presence or additional possibility of one or more other features, numbers, steps, operations, components, parts, or combinations thereof.

[0014] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which the embodiments pertain. Terms as defined in commonly used dictionaries should be interpreted to have a meaning consistent with the meaning they have in the context of the relevant art, and should not be interpreted in an idealized or overly formal sense unless expressly defined in this application.

[0015] The advantages and features of the present invention, as well as methods for achieving them, will become apparent from the following detailed description of the embodiments in conjunction with the accompanying drawings. However, the present invention is not limited to the embodiments disclosed below, and may be embodied in various different forms. However, these embodiments are provided solely to complete the disclosure of the present invention and to fully convey the scope of the invention to those skilled in the art. The present invention is defined only by the scope of the claims.

[0016] In the embodiments of the present invention, unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by a person of ordinary skill in the art to which the present invention pertains. Terms as defined in commonly used dictionaries should be interpreted to have a meaning consistent with the meaning they have in the context of the relevant art, and should not be interpreted in an idealized or overly formal sense unless expressly defined in this application.

[0017] The shapes, sizes, ratios, angles, numbers, etc. disclosed in the drawings for illustrating the embodiments of the present invention are merely illustrative, and the present invention is not limited to the illustrated details. Furthermore, when describing the present invention, if a detailed description of related prior art is deemed to unnecessarily obscure the gist of the present invention, such a detailed description will be omitted. When terms such as "comprise," "have," and "consist" are used in this specification, other parts may be added unless "only" is used. When a component is expressed in the singular, it also includes the plural unless otherwise explicitly stated.

[0018] When interpreting elements, they are interpreted as including a margin of error even if there is no other explicit description.

[0019] The size and thickness of each component shown in the drawings are shown for convenience of explanation and are not necessarily limited to the size and thickness of the components shown in the present invention.

[0020] The features of the various embodiments of the present invention may be partially or fully combined or combined with each other, and various technical interlocking and driving mechanisms are possible, as will be fully understood by those skilled in the art. Each embodiment may be implemented independently of the others, or may be implemented together in a related relationship.

[0021] The present invention will now be described in detail with reference to examples and drawings, but it is to be understood that the present invention is not limited to the following examples and drawings.

[0022] Hangover relief and liver function improvement Traditional hangover relievers have primarily consisted of substances that aid in liver metabolism. However, substances that address the chronic effects of alcohol consumption often have limited effectiveness during the acute phase. The inventors analyzed the acute phase reactions of the liver, gastrointestinal tract, and blood that occur during heavy drinking and recognized the need to address the primary factors that cause hangovers from a medical perspective. Based on this, the present inventors developed the present invention with the goal of minimizing the effects of alcohol absorption in the gastrointestinal tract, liver, and blood. More specifically, the present invention aims to: 1) enhance alcohol breakdown in the gastrointestinal tract; 2) inhibit alcohol absorption in the gastrointestinal tract; 3) improve the efficiency of alcohol metabolism in the liver and inhibit hangover-inducing substances; and 4) minimize the systemic effects of alcohol in the bloodstream through the process of absorption inhibition, metabolism promotion, minimization of systemic symptoms, and excretion promotion.

[0023] Approximately 10% of ethanol (officially ethyl alcohol) absorbed through drinking is excreted from the body through breathing and urination. Of the remaining 90%, 20% is absorbed in the stomach and 80% in the small intestine. Alcohol absorbed through the gastrointestinal mucosa does not require a special container and is rapidly absorbed into the liver via the bloodstream. It mixes with blood from the portal vein venules and hepatic arterioles, is exposed to hepatocytes, undergoes metabolism, and is absorbed into the central artery. Alcohol that passes through this pathway is oxidized in hepatocytes and converted into non-toxic acetate, which is used as energy (1 gram of alcohol contains approximately 7.1 kcal). Because the rate of hepatocyte metabolism is limited, any alcohol that remains unmetabolized enters the bloodstream, leading to a rise in blood alcohol concentration. Excess alcohol that is not oxidized enters the bloodstream, circulates throughout the body, and is metabolized again in the liver, resulting in a high blood alcohol concentration if you drink too much. Alcohol easily penetrates cell membranes and mixes well with cellular lipid membranes, disrupting normal cellular signal transmission. Alcohol also spreads to various organs through the systemic circulation, resulting in systemic symptoms. More than 90% of absorbed alcohol is metabolized into acetaldehyde in the liver, and is processed at a rate of about one ounce per hour.

[0024] The primary metabolic pathway of alcohol metabolism is broadly divided into 1) the alcohol dehydrogenase (ADH) system, 2) the microsomal ethanol oxidizing system (MEOS), and 3) the catalytic system. Of these, pathways 1) and 2) are clinically important. Pathway 1) is the main pathway of alcohol breakdown, in which alcohol is oxidized to acetaldehyde by the ADH enzyme present in the cytosol of hepatocytes. The intermediate product, acetaldehyde, is a highly unstable and toxic substance that is one of the main causes of liver damage (causing hangover symptoms such as facial flushing, tachycardia, headache, and nausea). This acetaldehyde is rapidly converted to acetic acid by acetaldehyde dehydrogenase (ALDH) present in the mitochondria (secondary metabolic pathway). The metabolism of acetaldehyde in mitochondria occurs quickly, but it occurs slowly in Asians, who have a high prevalence of ALDH mutations. This leads to the accumulation of acetaldehyde, which is considered a major cause of hangovers. Increased acetaldehyde levels lead to various hangover symptoms and inflammatory responses. Pathway 2 accounts for 10-20% of alcohol metabolism and metabolizes various drugs. Pathway 2 occurs when excessive drinking results in insufficient alcohol metabolism in the ADH pathway, resulting in the oxidation of ethanol to acetaldehyde. Repeated drinking over a long period of time can increase enzyme activity by 5-10 times, resulting in the perception of increased alcohol consumption. More specifically, two electrons from NADPH are transferred to CYP2E1 (cytochrome P450), a membrane protein located in the hepatocyte endoplasmic reticulum membrane, where ethanol is oxidized to acetaldehyde. This process generates reactive oxygen species (ROS). ROS are converted into hydrogen peroxide (H2O2), which attacks cell membranes (lipids) and inhibits the electron transport chain and oxidative phosphorylation process, causing cells to undergo an inflammatory response and die. Long-term exposure to ROS can lead to diseases such as liver cirrhosis.When a large amount of acetaldehyde, an intermediate substance in the secondary metabolic process of alcohol metabolism, accumulates, it cannot be converted to acetic acid at a certain rate and diffuses into the bloodstream, causing systemic symptoms (hangover symptoms such as vomiting, flushing, and nausea). Acetaldehyde is metabolized by ALDH in the mitochondria into acetate, the final oxidation product.

[0025] During the primary and secondary metabolic processes, the reduced product NADH increases, and the ratio of NADH / NAD + The ratio of NADH increases. This increase in NADH causes metabolic disruptions. In typical aerobic metabolic processes, carbohydrates, fats, and proteins are metabolized through the TCA cycle to produce NADH, which is then converted into ATP to generate energy. When NADH increases due to alcohol consumption, typical aerobic metabolic processes are suppressed. Because there is sufficient NADH, metabolic processes (glycolysis, gluconeogenesis, the TCA cycle (energy production), and fatty acid oxidation) proceed in a way that suppresses energy production. This suppression of energy production leads to hypoglycemia. As a result of alcohol metabolism, acetic acid accumulates, leading to the accumulation of fat, and lactic acid is produced, causing fatigue. Fasting blood sugar levels drop or remain lower than usual, and postprandial blood sugar levels rise.

[0026] In addition, alcohol consumption induces a diuretic effect, leading to potassium deficiency, which in turn impairs cellular response to ROS and severely reduces ATP production. Potassium depletion, in turn, interferes with the secretion of antidiuretic hormone (ADH) produced in the posterior pituitary gland, exacerbating hyponatremia. For example, potassium loss stimulates ADH activity, increasing fluid reabsorption and ultimately decreasing the body's sodium concentration. Potassium loss can also increase thirst and fluid intake through hormonal mechanisms. When potassium in the extracellular fluid (ECF) is deficient, potassium is transferred from the intracellular fluid (ICF) to the extracellular fluid due to the concentration difference. This results in a decrease in potassium in the cytoplasm. Meanwhile, although the inner mitochondrial membrane is not highly permeable to cations, a certain amount of potassium flows into the mitochondrial matrix, depending on the concentration difference. This influx of potassium allows the mitochondrion to maintain its volume, keep the membrane tight, and maintain the potential difference. When cytoplasmic potassium decreases, K transport to the mitochondrial matrix increases. + The outflow is reduced, and as a result, the mitochondria also become deficient in potassium. This tends to lead to a general decrease in mitochondrial function, including energy production. In this way, poor ATP synthesis and cellular respiration are conditions that make it easy for ROS to be formed. NADH / NAD +In a hyperreduced state, excess electrons are easily transferred to and combined with oxygen, resulting in the generation of ROS. In addition, excessive drinking also generates large amounts of ROS during the alcohol breakdown process via the microsomal ethanol oxidizing system (MEOS). ROS contribute to inflammation, aging, cancer, and degenerative diseases. Under stressful conditions that generate ROS, mitochondria activate ATP-dependent potassium channels, allowing potassium to enter the mitochondrial matrix. This reduces the membrane potential, reduces superoxide anion production, and suppresses ROS generation. Therefore, maintaining cytoplasmic potassium levels can suppress ROS generation, suppress inflammatory responses, and normalize mitochondrial function. Since acetaldehyde is broken down in mitochondria via ALDH, this activity can also be expected to be activated. Potassium supplementation is expected to suppress both inflammatory responses and acetaldehyde production, which are considered to be the main causes of hangovers.

[0027] Based on these findings, the inventors concluded that the direct cause of hangovers is blood cytokines, rather than alcohol and acetaldehyde, based on the following: 1) blood ethanol concentration reaches its peak 60-90 minutes after drinking and then decreases over time; 2) blood acetaldehyde reaches its peak within one hour of drinking; and 3) hangover symptoms peak 12-14 hours after drinking (at which point alcohol and acetaldehyde have been largely metabolized). In particular, the inventors found that the onset of cytokines after alcohol exposure coincides with the onset of hangover symptoms, and that injection of cytokines into healthy individuals produces hangover-like symptoms, such as gastrointestinal disorders, headache, chills, fatigue, and vomiting. The inventors hypothesized that the primary cause of hangovers is a decrease in cellular immunity mediated by IL-10 and IL-12 (IL-10 and IL-12).

[0028] Fatigue recovery In one aspect, the present invention provides a food composition for fatigue recovery. Ammonia closely reflects the state of fatigue during exercise. The central fatigue mechanism of ammonia is that when toxic ammonia accumulates in large amounts, it can cause motor dysfunction, such as lethargy, convulsions, ataxia, and coma. The peripheral fatigue mechanism is that ammonia accumulation in muscles can stimulate afferent nerves related to the perception of muscle pain, leading to fatigue. The composition of the present invention can reduce the concentrations of fatigue-causing substances ammonia, cortisol, and lactic acid in the blood and rapidly increase the hydrogen ion concentration (pH), thereby effectively alleviating fatigue after exercise.

[0029] Food composition for relieving hangovers and improving liver function In one aspect, the present invention provides a food composition for relieving hangovers and improving liver function, comprising L-ornithine, potassium citrate, cabbage powder, and one or more lactic acid bacteria selected from the group consisting of bifidobacteria and lactobacilli.

[0030] In particular, the inventors discovered that when the above-mentioned ingredients are contained in a composition as active ingredients, they exert a sufficient hangover relief effect while minimizing the burden on the human body, and thus completed the present invention. They have found a way to approach hangover relief from a medical perspective by using safe substances approved for use as foods. The composition of the present invention can be used to relieve hangovers and improve liver function.

[0031] In the present invention, the term "extract" refers to an active ingredient isolated from a natural product. It can be obtained through an extraction process using water, an organic solvent, or a mixture thereof. It includes the extract, its dried powder, and all forms of preparations using the extract. The extracted liquid can be used immediately or can be concentrated and / or dried to form a powder. When using an organic solvent, the extract can be extracted at room temperature or heated under conditions that do not destroy or minimize the active ingredient, using organic solvents such as methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixture thereof. The organic solvent used for extraction can vary in the degree of extraction and loss of the active ingredient, so it is important to select an appropriate organic solvent. The extraction method is not particularly limited and includes, for example, hot water extraction, cold maceration extraction, ultrasonic extraction, and reflux extraction.

[0032] The solvent extract may further include a step of filtering the extract to remove suspended solid particles. Filtering may be performed using cotton, nylon, or other suitable methods, such as ultrafiltration, freeze filtration, and centrifugation. Concentrating the extract may involve methods such as vacuum concentration and reverse osmotic concentration. Drying after concentration may involve methods such as freeze drying, vacuum drying, hot air drying, spray drying, vacuum drying, foam drying, microwave drying, and infrared drying, but is not limited to these.

[0033] The composition of the present invention 1) inhibits alcohol absorption, 2) activates the breakdown of alcohol and its by-products, and 3) inhibits inflammatory responses caused by alcohol and its by-products. More specifically, when excessive alcohol is consumed, the composition of the present invention inhibits absorption in the gastrointestinal tract, promotes breakdown in the liver, and inhibits the production of inflammatory substances, thereby maintaining optimal liver function and facilitating metabolism. The composition of the present invention is taken with or immediately after drinking alcohol, and is therefore effective in the short term, particularly in resolving symptoms that occur during the acute phase.

[0034] The inventors have named the composition of the present invention, which has hangover relief and liver function benefits, "Morning WOW."

[0035] The term "active ingredient" refers to an ingredient that exhibits a desired activity or an ingredient that can exhibit the activity together with an inactive carrier.

[0036] L-ornithine is a basic amino acid that plays an important role as an intermediate in the urea cycle. In the urea cycle, L-ornithine enters mitochondria from the cytoplasm, where it captures ammonia and is synthesized into L-citrulline. It then enters the cytoplasm and becomes argininosuccinate, which removes nitrogen groups from the mitochondria. Argininosuccinate then transfers the second amino group of urea from aspartate, which then removes the carbon group from fumarate and transfers the nitrogen group to arginine, synthesizing harmless urea. Urea is then excreted through the kidneys. Two major cycles operating in the body are the citric acid cycle (TCA cycle), which produces energy, and the urea cycle, which processes ammonia. The citric acid cycle occurs within the mitochondria, while the urea cycle occurs between the cytoplasm and mitochondria. The two cycles share intermediate metabolic products (argininosuccinate shunt) and interact with each other, such as using some of the ATP (4ATP) produced in the citric acid cycle in the urea cycle. Amino acids produce the toxic substance ammonia (a nitrogenous compound) as a metabolic product, which is converted into harmless urea through the urea cycle and excreted through the kidneys.

[0037] Under alcohol drinking conditions, ADH preferentially accelerates alcohol decomposition over mitochondrial metabolism of other nutrients, resulting in the accumulation of NADH and a high NADH / NAD+ ratio. + The TCA cycle, which converts NADH to NADH, is slowed down. Oxaloacetate in the TCA cycle receives the amino group of glutamate to become aspartate, which then transfers the amino group to the urea cycle via argininosuccinate. However, in the case of alcohol, the NADH / NAD +When the urea cycle is high, aspartate is metabolized to a pathway that produces oxaloacetate and reduces NADH. As a result, the amino group of aspartate is not transferred to the urea cycle, but to α-ketoglutarate, which produces glutamate. This can lead to decreased removal of amino groups in hepatocytes, leading to the accumulation of ammonium ions, which is linked to mitochondrial dysfunction. The present invention supplements ornithine, which enters mitochondria and scavenges nitrogen groups.

[0038] L-ornithine directly enters mitochondria, captures ammonia nitrogen, converts it to citrulline, and then exports it to the cytoplasm. In situations where ammonia removal is reduced due to elevated blood alcohol levels, L-ornithine directly promotes ammonia removal. Furthermore, it is expected to maximize the nitrogen removal effect of ornithine by supplying carbon dioxide, which is necessary for carbamoyl phosphate, produced during the process of transferring ammonium to ornithine, to mitochondria. The present invention focuses on preventing the accumulation of amino groups within mitochondria and normalizing mitochondria. To this end, potassium citrate was added to replenish carbon dioxide, the production of which is slowed due to a slowdown in the TCA cycle. Effective removal of ammonia within mitochondria normalizes mitochondrial acetaldehyde degradation, leading to reduced ROS generation and subsequent circulation, thereby normalizing mitochondria and ultimately promoting the decomposition of acetaldehyde by mitochondrial ALDH.

[0039] The "potassium citrate" acts as an alkalizing agent as an alkaline organic salt compound. Potassium citrate has a buffering effect on gastric acidity, which is thought to be manifested by chloride ions before absorption and bicarbonate after absorption. The potassium citrate is 90% ionized at physiological pH, and the ionized citric acid acts as a trivalent anion. In the human body, it reduces blood bicarbonate ions (HCO3 - ) and hydrogen ions (H+ ) are converted into water and carbon dioxide in equilibrium (HCO3- + H + <->H2O+CO2). The citric acid released into the blood is + Combines with HCO3 - It has the effect of releasing lactic acid into the blood, and therefore acts as an alkali. This can be expected to prevent lactic acidosis in the blood, which occurs when lactic acid is produced after excessive drinking, and to be effective in preventing one of the causes of hangovers. Potassium citrate is quickly absorbed through the gastrointestinal tract. Substances absorbed in the gastrointestinal tract immediately flow into the liver and into hepatocytes. When lactic acid is produced in the state of excessive drinking, citric acid is better ionized near the acidic liver cells, and H + and HCO3 - It releases CO2, which increases blood pH and normalizes blood pH. Meanwhile, CO2 generated in this process diffuses smoothly into the inner mitochondrial membrane, which is highly permeable to gases. Potassium citrate plays a role in supplying carbon dioxide and potassium directly to hepatocytes. In order to convert nitrogen groups into urea in the urea cycle, NH 4+ and carbon dioxide must react to form carbamoyl phosphate. When drinking too much, the TCA cycle cannot function smoothly and less CO2 is produced, so it can be predicted that a smooth supply of external CO2 is necessary to activate the urea cycle. At this time, the citric acid in potassium citrate is H + When L-ornithine reacts with ammonium chloride to form water and carbon dioxide, the carbon dioxide enters the cells, temporarily causing hypercarbia. This allows carbon dioxide to pass smoothly through the inner mitochondrial membrane and provide the carbon dioxide needed to form carbamoyl phosphate. Therefore, potassium citrate activates the metabolic process in which L-ornithine captures ammonia groups within the mitochondria and converts them into citrulline. As a result, it can be expected to prevent the accumulation of ammonia groups within liver cells, normalize mitochondria, and facilitate the removal of acetaldehyde.

[0040] Drinking alcohol causes a large amount of potassium to be excreted. As potassium in the extracellular fluid decreases, an extracellular shift occurs. As a result, cells allow potassium to flow into the cells through Na / K ATPase, causing the cells to use more ATP. In order for liver cells to cope with the ROS generated during the alcohol breakdown process, K + However, when alcohol is consumed, potassium is excreted, resulting in a potassium deficiency.

[0041] By replenishing potassium, hepatocytes, which have more difficulty dealing with ROS due to potassium deficiency, can be activated. The potassium citrate is absorbed through the gastrointestinal tract faster than other potassium-containing preparations, being absorbed within a few hours and reaching hepatocytes quickly, providing potassium directly to hepatocytes. The supply of potassium reduces ROS generated in mitochondria, which is expected to reduce the inflammatory response caused by ROS later. Therefore, it can be expected to contribute to alleviating hangovers after drinking. On the other hand, when the pH is low, H + Due to the properties of citric acid, which reacts with H + It is expected that it will react with and raise the pH of the stomach. When drinking alcohol, excess stomach acid is secreted, but by neutralizing this, it is expected to alleviate symptoms that appear immediately after drinking, such as stomach irritation, nausea, and vomiting.

[0042] The inventor is K + Direct influx of K into hepatocytes + To prevent this depletion, potassium citrate was used as an active ingredient. Meanwhile, citrate salts can be expected to contribute to the activation of the urea cycle by supplying carbon dioxide radicals, along with L-ornithine. In particular, potassium citrate is absorbed more quickly through the gastrointestinal tract than other ingredients, reaching liver cells more quickly and contributing significantly to the breakdown of alcohol.

[0043] The cabbage powder is an ingredient for protecting the stomach during alcohol intake. It is obtained by shredding cabbage, drying it, removing moisture, and then grinding it. Cabbage powder is a natural anti-ulcer food containing ingredients that protect and strengthen the gastric mucosa, making it effective in preventing cancers such as stomach cancer and colon cancer. It is also rich in dietary fiber and low in calories, making it effective for weight loss, preventing constipation, and preventing skin aging. The inventors formulated cabbage powder as an active ingredient to exert the effects of dietary fiber, including inhibiting alcohol absorption, antioxidant / anti-inflammatory effects, and promoting the decomposition of acetaldehyde, in addition to protecting the gastric mucosa. Furthermore, sulforaphane contained in the cabbage powder has excellent antioxidant effects, cell stress reduction effects, and inflammation reduction effects when oxidative stress is induced in cells. Furthermore, sulforaphane is found in the salivary glands and activates hsALDH, a normally inactive isoform of ALDH, to induce ALDH and break down acetaldehyde, making it useful for people who have difficulty breaking down acetaldehyde due to ALDH gene mutations. ALDH mutations are estimated to affect approximately 30% of the Korean population. This reduces oxidative stress in liver cells caused by ROS generated during excessive alcohol consumption, promotes the breakdown of acetaldehyde, and effectively reduces the resulting inflammation.

[0044] Alcohol is transported through the bloodstream to the large intestine, where the blood alcohol concentration and the large intestine alcohol concentration become equal. In other words, the large intestine reaches its peak alcohol concentration 30 to 90 minutes after drinking, when blood alcohol concentration is at its highest. In the large intestine, acetaldehyde is produced through alcohol-to-acetaldehyde metabolism by the ADH of colonic bacteria. Because colonic flora has significantly lower ALDH activity than ADH, acetaldehyde concentrations are highest in the body in the large intestine. Generally, ingested food takes more than nine hours to reach the large intestine, and acetaldehyde is produced before lactic acid bacteria are transported to the large intestine with the food. Therefore, it is expected that lactic acid bacteria consumed before drinking will not have a significant effect on the removal of acetaldehyde on the day of drinking. Therefore, cabbage is useful as a dietary fiber because it stimulates overall intestinal motility, increases intestinal speed and speeds defecation, reduces the absorption of already produced acetaldehyde into the blood, and provides bulk to promote intestinal motility. In particular, heat-treated cabbage powder is effective in treating hepatitis inflammation by reducing the expression of inflammatory mediators iNOS and COX-2 and the proinflammatory cytokine IL-1β, which are involved in the acute inflammatory response associated with liver injury. The cabbage powder used in this invention is heat-treated at approximately 121°C. Furthermore, MMSC (s-methylmethionine sulfonium chloride), a representative anti-peptic ulcer factor in cabbage, promotes the production of prostaglandin, a local hormone secreted in the gastric mucosa, and the prostaglandin secreted into the gastric cavity provides the gastric mucosa with the ability to defend itself against gastric acid and other attacking factors.

[0045] As mentioned above, the cabbage powder used in the present invention is not a juice obtained from freeze-dried cabbage, but is a heat-treated cabbage powder containing insoluble dietary fiber. Therefore, in addition to the cabbage's effect of suppressing acute gastritis, it also exhibits the effect of insoluble dietary fiber, which absorbs water, increases stool volume, shortens intestinal transit time, and prevents constipation and bowel inflammation. Furthermore, since the lactic acid bacteria used in this patented material are mixed with dietary fiber, early alcohol degradation by ADH in the lactic acid bacteria can be expected. Therefore, not only does it have an anti-inflammatory effect in the stomach, but it also absorbs alcohol in the small intestine, the main site of alcohol absorption, thereby slowing the alcohol absorption rate and promoting alcohol degradation by the lactic acid bacteria mixed with the cabbage, thereby promoting excretion. Furthermore, it is expected to be useful in alleviating hangovers by reducing ROS generated in the liver and promoting the breakdown of acetaldehyde, thereby reducing inflammatory responses.

[0046] Almost all species of Bifidobacteria and Lactobacillus have the ability to break down alcohol and / or acetaldehyde. Therefore, when administered together with cabbage, which is a dietary fiber, they can break down the alcohol absorbed by the cabbage, and are expected to have an alcohol-decomposing effect in the early stages of drinking.

[0047] The "Bifidobacteria" are a genus of Gram-positive, non-motile, and often classified as anaerobic bacteria. They are found in the gastrointestinal tract, vagina, and mouth of mammals. Bifidobacteria are one of the major genera of bacteria that make up the colon flora in mammals. Bifidobacterium organisms are commercially available and sold as probiotics for human consumption. See, for example, Dr. Mercola R Complete Probiotics capsules by Align Biotech contain three species of bifidobacteria and contain 70 billion organisms. Other commercial sources of bifidobacteria are also commonly used (e.g., Align Biotech). R Bifantis RBifidobacterium infantis 35624). Any species of bifidobacteria that may be used in the present invention is suitable, as strains of this genus are known to live and function in the human digestive tract and are known to be safe for human consumption. Such strains that may be used in the methods and compositions of the present invention include, but are not limited to, B. infantis, B. breve, B. adolescentis, B. animalis, B. pseudolongum, B. thermophilum, B. indicum, B. asteroides, B. lactis, B. longum, B. coagulans, B. dentium, B. infantis, B. animalis ssp. lactis, and B. bifidum.

[0048] The "Lactobacillus" is a Gram-positive, facultative, anaerobic or microaerophilic, rod-shaped bacterium. This genus constitutes a major part of the group of bacteria (lactic acid bacteria) that convert lactose and other sugars to lactic acid. They are found in the human gastrointestinal tract and vagina. Some strains of Lactobacillus have potential therapeutic properties, including anti-inflammatory and anti-cancer abilities. They also promote the healing of gastric ulcers. There are various commercial sources of Lactobacillus (e.g., Health & Wellness 30-Capsules or Digestive Health 30-Capsules sold by Culturelle). R ,Cromwell,Connecticut;Nutrition Now R Pro-Biotics Acidophilus from GNC;FoodScience Rof Vermont Lactobacillus Acidophilus capsules). Any species of Lactobacillus that can be used in the present invention is suitable, as strains of that genus are known to live and function in the human digestive tract and are known to be safe for human consumption. Such strains that can be used in the methods and compositions of the present invention include, but are not limited to, L. acidophilus (e.g., L. acidophilus DDS-1, L. acidophilus LA-5, L. acidophilus NCFM), L. bulgaricus, L. jugurti, L. helveticus, L. salivarius, L. casei, L. plantarum, L. salivarius, L. rhamnosus (e.g., L. rhamnosus A), L. paracasei, L. lactis, L. infantis, and L. brevis.

[0049] The "Bifidobacteria" and "Lactobacillus" are representative genera used in probiotic lactic acid bacteria. The acidity, the time of exposure to acid, and the type of strain are major factors that affect the survival of lactic acid bacteria in the gastrointestinal tract. Among these, the "Bifidobacteria" and "Lactobacillus" are widely used in lactic acid bacteria products because they can survive in an acidic environment. In particular, L. acidophilus and B. longum survive better in the gastrointestinal tract and adhere better to the gastric mucosa.

[0050] Alcohol is primarily absorbed in the small intestine, causing barrier damage. Lactic acid bacteria ameliorate this damage, reducing endotoxin absorption and liver damage. Oxidative stress generated in the intestine by alcohol damages the tight junctions of intestinal epithelial cells, increasing intestinal permeability. Acetaldehyde also increases intestinal permeability by destroying microtubules within intestinal epithelial cells. Increased intestinal permeability allows endotoxins present in the cell walls of gram-negative bacteria in the intestine to enter the bloodstream, promoting the secretion of inflammatory cytokines such as TNF-α, IL-1, and IL-6, leading to liver cell damage (https: / koreascience.kr / article / JAKO201409649928775.pdf). These inflammatory cytokines are also found in alcohol metabolism, suggesting that increased intestinal permeability due to alcohol consumption may exacerbate liver damage. Lactic acid produced by lactic acid bacteria promotes the proliferation of intestinal stem cells and regenerates intestinal mucosal epithelial cells. The bifidobacteria and lactobacillus used in this patent have excellent resistance to gastric acid, producing lactic acid in the small intestine and promoting the proliferation of intestinal stem cells, which is expected to help repair intestinal mucosa damaged by alcohol consumption. This contributes to reducing liver damage caused by excessive drinking and is expected to alleviate hangovers. Because food takes time to reach the large intestine, and acetaldehyde is produced in the large intestine immediately after drinking and reaches its peak concentration before food reaches the large intestine, the degree of alcohol breakdown during the early stages of drinking determines the next day's hangover. Therefore, the present invention focuses on the contribution of lactic acid bacteria to repair small intestinal damage rather than the acetaldehyde breakdown of lactic acid bacteria, which occurs mainly during the later stages of drinking. The lactic acid bacteria used in this invention are lactobacillus, which has excellent resistance to gastric acid, and bifidobacteria, which are abundant in the large intestine. As a result, the combination of "Bifidobacteria" and "Lactobacillus" lactic acid bacteria can reduce the stomach irritation caused by alcohol and alleviate erosive gastritis, stomach irritation, and nausea. Furthermore, the proliferation of the lactic acid bacteria is promoted in the presence of dietary fiber, so it shows an enhancing effect on the healing of stomach ulcers when combined with cabbage powder.

[0051] In one embodiment, the L-ornithine is contained in an amount of 15 to 30 wt % based on the total weight of the composition, the potassium citrate is contained in an amount of 2 to 12 wt % based on the total weight of the composition, the cabbage powder is contained in an amount of 30 to 50 wt % based on the total weight of the composition, and the lactic acid bacteria is contained in an amount of 2 to 14 wt % based on the total weight of the composition.

[0052] More specifically, the L-ornithine is contained in an amount of 15% by weight or more, 16% by weight or more, 17% by weight or more, 18% by weight or more, 19% by weight or more, 20% by weight or more, 21% by weight or more, 22% by weight or more, 23% by weight or more; 30% by weight or less, 29% by weight or less, 28% by weight or less, 27% by weight or less, 26% by weight or less, 25% by weight or less, 24% by weight or less, 23% by weight or less, based on the total weight of the composition.

[0053] In one embodiment, the potassium citrate is contained in an amount of 2 to 12 wt % based on the total weight of the composition. More specifically, the potassium citrate is contained in an amount of 2 wt % or more, 3 wt % or more, 4 wt % or more, 5 wt % or more, 6 wt % or more, 6.7 wt % or more, 12 wt % or less, 11 wt % or less, 10 wt % or less, 9 wt % or less, 8 wt % or less, 7 wt % or less, or 6.7 wt % or less based on the total weight of the composition.

[0054] More specifically, the cabbage powder is contained in an amount of 30% by weight or more, 31% by weight or more, 32% by weight or more, 33% by weight or more, 34% by weight or more, 35% by weight or more, 36% by weight or more, 37% by weight or more, 38% by weight or more, 39% by weight or more, 40% by weight or more; or 50% by weight or less, 49% by weight or less, 48% by weight or less, 47% by weight or less, 46% by weight or less, 45% by weight or less, 44% by weight or less, 43% by weight or less, 42% by weight or less, 41% by weight or less, 40% by weight or less, based on the total weight of the composition.

[0055] More specifically, the lactic acid bacteria are contained in an amount of 2% by weight or more, 3% by weight or more, 4% by weight or more, 5% by weight or more, 6% by weight or more, 7% by weight or more; 14% by weight or less, 13% by weight or less, 12% by weight or less, 11% by weight or less, 10% by weight or less, 9% by weight or less, 8% by weight or less, 7% by weight or less, 6% by weight or less, based on the total weight of the composition.

[0056] In one embodiment, the L-ornithine, potassium citrate, cabbage powder, and lactic acid bacteria are contained in the food composition in a weight ratio of 2-5:1-2:4-10:1-2, or a weight ratio of 3-4:1-2:5-8:1-2, or a weight ratio of 3-4:1-2:5-7:1-2.

[0057] In one embodiment, the food composition further comprises water dropwort powder.

[0058] The water dropwort (Oenanthejavanica) powder contains persicarin, which activates enzymes related to alcohol metabolism. Water dropwort is a perennial herb of the Umbelliferae family that grows wild throughout Korea and is widely distributed in regions from the subarctic to tropical regions, including China and Japan, where it is cultivated for food.

[0059] The water parsley powder is contained in an amount of 3 to 13% by weight based on the total weight of the composition. More specifically, the water parsley powder is contained in an amount of 3% by weight or more, 4% by weight or more, 5% by weight or more, 6% by weight or more, 7% by weight or more, 8% by weight or more, 8.14% by weight or more, 13% by weight or less, 12% by weight or less, 11% by weight or less, 10% by weight or less, 9% by weight or less, or 8.14% by weight or less based on the total weight of the composition.

[0060] In one embodiment, the food composition further comprises turmeric extract.

[0061] The pharmacological effects of turmeric extract include promoting bile secretion, uterine stimulation, hypotensive, and analgesic effects. It has been proven to inhibit the growth of Staphylococcus aureus and fungi, and to reduce hyperlipidemia [Korean Materia Medica, by Ahn Deok-jun]. Turmeric (Curcuma Longa L.) is the rhizome of the perennial herb Curcuma longa L. Turmeric is primarily cultivated in the rainy subtropical regions from southern China to Southeast Asia. It grows abundantly in the wild in the forests of South and Southeast Asia. Turmeric contains cocumin and essential oil components such as turmerone, zingerene, phellandrene, cineole, sabinene, bornol, and dehydroturmerone. Cocumin, a type of polyphenol, exerts hepatoprotective and systemic inflammatory responses through its anti-inflammatory and antioxidant properties. More specifically, it modifies NF-κB signaling and exerts anti-inflammatory effects by participating in inflammatory cytokines (interleukins, COX2 and COX5, which inhibit the production of phospholipase A2).

[0062] The turmeric extract is contained in an amount of 3 to 13 wt % based on the total weight of the composition. More specifically, the turmeric extract is contained in an amount of 3 wt % or more, 4 wt % or more, 5 wt % or more, 6 wt % or more, 7 wt % or more, 8 wt % or more, 13 wt % or less, 12 wt % or less, 11 wt % or less, 10 wt % or less, 9 wt % or less, or 8 wt % or less based on the total weight of the composition.

[0063] According to one embodiment of the present disclosure, the composition is a health functional food composition. In one embodiment, the health functional food can be prepared in any one of the following forms: powder, granules, pills, tablets, capsules, or beverages by incorporating the food composition. The preparation method may be, but is not limited to, baking or far-infrared radiation.

[0064] The term "health functional food" refers to food that is manufactured and processed for the purpose of health supplementation by using specific ingredients as raw materials or by extracting, concentrating, purifying, mixing, etc., specific ingredients contained in raw materials, and refers to food that is designed and processed so that the ingredients can fully exert bioregulatory functions such as biodefense on the living body, and can perform functions related to disease prevention, improvement, or health restoration.

[0065] The types of health functional foods in which the extracts of the present disclosure can be used are not particularly limited. Examples include ramen and other noodles, beverages, tea, health supplements, alcoholic beverages, various soups, meats, sausages, bread, chocolate, candies, snacks, pizza, gum, dairy products including ice cream, and vitamin complexes. The health functional foods may be in the form of powder, granules, tablets, capsules, or beverages, preferably beverages. When used in health functional foods, the extracts of the present disclosure can be added directly or in combination with other foods or food ingredients, which can be selected and used appropriately as needed. In addition to the extracts of the present disclosure, other appropriate auxiliary ingredients and known additives that are commonly included in health functional foods can be mixed in accordance with the selection of a skilled artisan.

[0066] Method for producing food composition for hangover relief and liver function improvement In another aspect, the present invention provides a method for producing a food composition for relieving hangovers and improving liver function, comprising the steps of: mixing a powdered raw material containing one or more lactic acid bacteria selected from the group consisting of L-ornithine, potassium citrate, cabbage powder, bifidobacteria, and lactobacillus with water to produce a mixture; forming the mixture into pellets to produce pellet precursors; shaping the pellet precursors to form them with smooth surfaces; and drying the pellet precursors with smooth surfaces to produce pellets.

[0067] In another aspect, the present invention provides a method for preparing a food composition for relieving hangovers and improving liver function, the method comprising the steps of: extracting and drying cabbage to prepare cabbage powder; and mixing the cabbage powder with L-ornithine, potassium citrate, and one or more lactic acid bacteria selected from the group consisting of bifidobacteria and lactobacillus.

[0068] In the method for preparing the extract according to one embodiment of the present invention, the freeze-dried raw material is crushed, and then distilled water is added thereto and extracted at 75-85°C for 2-4 hours. Preferably, the freeze-dried raw material is added with distilled water and extracted at 80°C for 3 hours three times.

[0069] According to an embodiment of the present invention, the step of preparing the powder may be performed before the step of mixing, after the step of mixing, or simultaneously with the step of mixing.

[0070] In one embodiment, the powdered raw material and water are mixed in a weight ratio of 1 to 3:1, more specifically, in a weight ratio of 7:3.

[0071] In one embodiment, the diameter of the round precursor is 4 to 6 mm, more specifically, 5 mm.

[0072] In one embodiment, the method further includes packaging the round pieces into a square or rectangular four-sided packaging container.

[0073] In one embodiment, the drying is carried out at 35°C to 37°C for 60 to 72 hours.

[0074] In one embodiment, the manufacturing method includes the steps of mixing the powdered raw materials; kneading the mixed raw materials and water in a mixer; molding the dough into balls in a ball-making machine; molding the balls into a molding machine; drying the molded balls in a dryer; sorting the dried balls into a ball sorter to remove defective balls; and packaging the sorted balls in four-sided wrapping paper; moving the packaged semi-finished products to a packaging room and packaging them in boxes for separate case packaging and shipping; and moving the box-packaged finished products to a shipping waiting area. [Example]

[0075] The present disclosure will be described in detail below with reference to examples. However, the following examples are merely illustrative examples for general understanding of the present disclosure, and the contents of the present disclosure are not limited to the following examples.

[0076] <Production Example 1> Production of a food composition for relieving hangovers and improving liver function Food compositions for relieving hangovers and improving liver function according to Examples 1 to 4 of the present invention were prepared according to the compositions shown in Tables 1 and 2 below.

[0077] [Table 1] [Table 2] [Table 3] [Table 4]

[0078] <Reference Example 1> Preparation of a composition according to a comparative example Compositions according to Comparative Examples 1 to 4 were prepared in the same manner as in Example 1, except that they did not contain L-ornithine, potassium citrate, cabbage powder, or lactic acid bacteria.

[0079] <Experimental Example 1> Evaluation of suppression of increase in alcohol concentration in the body The subjects were 10 men and women, aged 30-40, weighing 65-75 kg, and consumed 400 ml of alcohol (19.5% alcohol content). The initial alcohol concentration was measured 30 minutes after drinking, and then the subjects consumed 5 g of the health functional foods produced in each Example and Comparative Example. 90 minutes after drinking, the alcohol concentration (unit: mg / L) was measured using an alcohol checker. The difference in alcohol concentration 30 minutes after drinking and 90 minutes after drinking is shown in Table 5.

[0080] [Table 5]

[0081] <Experimental Example 2> Evaluation of Alcohol Hangover Severity Scale (AHSS) The subjects were 10 men and women, aged 30-50, weighing 65-75 kg. The subjects consumed 400 ml of alcohol (19.5% alcohol). The subjects were assessed for symptoms before and the day after drinking (0 = none, 10 = extreme). The results are shown in Table 6 (after: before).

[0082] [Table 6]

[0083] From Table 6, it can be seen that the severity of alcohol hangover was improved after taking the health functional food of the present invention.

[0084] <Dosage Form Example 1> Manufacturing of pills Pills were prepared in the usual manner according to the composition shown in Table 7 below.

[0085] [Table 7]

[0086] <Dosage Form Example 2> Manufacturing of pills Pills were prepared in the usual manner according to the composition shown in Table 8 below.

[0087] [Table 8]

[0088] <Dosage Form Example 9> Manufacturing of pills Healthy drinks were prepared in the usual manner according to the compositions listed in Table 9 below.

[0089] [Table 9]

[0090] Although the present invention has been described with reference to the preferred embodiments mentioned above, various modifications and variations can be made without departing from the spirit and scope of the invention, and it is therefore intended that the appended claims cover all such modifications and variations as fall within the spirit and scope of the invention.

Claims

1. one or more lactic acid bacteria selected from the group consisting of L-ornithine, potassium citrate, cabbage powder, bifidobacteria, and lactobacillus; A food composition for relieving hangovers and improving liver function, comprising:

2. The L-ornithine is contained in an amount of 15 to 30% by weight based on the total weight of the composition, The potassium citrate is contained in an amount of 2 to 12% by weight based on the total weight of the composition, The cabbage powder is contained in an amount of 30 to 50% by weight based on the total weight of the composition, 2. The food composition according to claim 1, wherein the lactic acid bacteria is contained in an amount of 2 to 12% by weight based on the total weight of the composition.

3. A step of mixing a powdered raw material containing L-ornithine, potassium citrate, cabbage powder, and one or more lactic acid bacteria selected from the group consisting of bifidobacteria and lactobacillus with water to prepare a mixture; forming the mixture into a pellet to produce a pellet precursor; shaping the round precursor to form a smooth surface; and a step of drying the round precursor having a smooth surface to produce a round; A method for producing a food composition for relieving hangovers and improving liver function, comprising:

Images